Understand the properties of chlorhexidine to support strategies to reduce central line-associated bloodstream infections (CLABSI).
Products may not be available in all countries. Midline with ARROWg+ard protection is currently not available in the EMEA region.
Please contact your local representative for more information.
4.9 central line-associated BSI (CLABSI) episodes per 1000 CVC-days.
Intensive care units (ICUs) are the hospital wards with the highest prevalence of healthcare-associated infections (HAIs). The majority of HAIs in ICUs are associated with the use of invasive devices, such as vascular catheters, and a significant proportion of these HAIs are considered preventable.2
We strive to be a trusted partner to clinicians, providing resources and support to help consistently align with CVC-related guidelines for the prevention of CLABSI.
References:
Contraindications:
The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs.
Clinical assessment of the patient must be completed to ensure no contraindications exist. Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas:
No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, and Arrowg+ard Blue Plus are trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners. MCI-102066
© 2025 Teleflex Incorporated. All Rights Reserved.
